Home / Compounds
The register
16 compounds. Each record follows the same six sections so you can compare them directly. UK status is stated first every time.
| Compound | Class | Evidence |
|---|---|---|
| SemaglutideOzempic, Wegovy, Rybelsus | GLP-1 receptor agonist | Human RCT, phase 3 |
| TirzepatideMounjaro | Dual GIP and GLP-1 receptor agonist | Human RCT, phase 3 |
| LiraglutideSaxenda, Victoza | GLP-1 receptor agonist | Human RCT, phase 3 |
| DulaglutideTrulicity | GLP-1 receptor agonist | Human RCT, phase 3 |
| OrforglipronFoundayo in the United States. No UK brand name yet | Non-peptide GLP-1 receptor agonist | Human RCT, phase 3 |
| RetatrutideNo brand name. Development code LY3437943 | Triple receptor agonist | Phase 3 ongoing |
| CagriSemaNo brand name. A combination of cagrilintide and semaglutide | Amylin analogue plus GLP-1 receptor agonist | Phase 3 reported, no approval |
| TesamorelinEgrifta | GHRH analogue | Human RCT for its licensed indication |
| SomatropinMultiple brands, including Genotropin, Norditropin, Humatrope | Recombinant human growth hormone | Human RCT for licensed uses |
| BPC-157Also written BPC 157, Bepecin, PL 14736 | Synthetic pentadecapeptide | Animal studies, almost no human data |
| TB-500Related to thymosin beta-4, often conflated with it | Synthetic peptide fragment | Animal studies, no human trials |
| CJC-1295Also sold as Mod GRF 1-29 or CJC-1295 no-DAC, which is a related but shorter-acting compound | GHRH analogue | No human trials supporting marketed claims |
| IpamorelinNo brand name. Sold as a research chemical, usually blended with CJC-1295 | Growth hormone secretagogue | Abandoned in development, no supporting human trials |
| AOD-9604Also written hGH 176-191 or hGH fragment 176-191 | Growth hormone fragment | Human trials did not support the claims |
| MK-677Ibutamoren, ibutamoren mesylate, sometimes sold as Nutrobal | Growth hormone secretagogue, non-peptide | Human trials exist, no approval |
| Melanotan IIMT-II, sold as tanning injections and nasal sprays | Synthetic melanocortin receptor agonist | Limited early human studies |
Licensed medicines
Assessed by the MHRA
These have marketing authorisations, meaning a regulator examined evidence on quality, safety and efficacy. All are prescription only. A licence is not a recommendation for any individual.
Semaglutide
GLP-1 receptor agonist
A licensed prescription medicine, and one of the two GLP-1 drugs most people are actually talking about.
Evidence: Human RCT, phase 3
Tirzepatide
Dual GIP and GLP-1 receptor agonist
The other licensed drug in this space, and the first approved anywhere to act on two hormone receptors at once.
Evidence: Human RCT, phase 3
Liraglutide
GLP-1 receptor agonist
The first GLP-1 drug most UK patients encountered. Daily rather than weekly, and now largely superseded.
Evidence: Human RCT, phase 3
Dulaglutide
GLP-1 receptor agonist
Widely prescribed on the NHS for type 2 diabetes. Not licensed for weight loss.
Evidence: Human RCT, phase 3
Unlicensed and investigational
Not assessed for human use
No marketing authorisation in the UK. Some are still in trials, some are sold as research chemicals, and one is a controlled drug. Supplying any of them for human use without authorisation is prohibited.
Orforglipron
Non-peptide GLP-1 receptor agonist
A GLP-1 pill that is not a peptide. Approved in the US, still under review here.
Evidence: Human RCT, phase 3
Retatrutide
Triple receptor agonist
Still in trials. Widely sold on the grey market, which is illegal and unverifiable.
Evidence: Phase 3 ongoing
CagriSema
Amylin analogue plus GLP-1 receptor agonist
Combines a GLP-1 drug with a copy of a second appetite hormone. Not approved anywhere yet.
Evidence: Phase 3 reported, no approval
Tesamorelin
GHRH analogue
A licensed medicine, but for one narrow condition and not in the UK. Sold well outside both.
Evidence: Human RCT for its licensed indication
Somatropin
Recombinant human growth hormone
A licensed medicine for defined conditions, and a controlled drug. Widely misused outside both.
Evidence: Human RCT for licensed uses
BPC-157
Synthetic pentadecapeptide
Heavily marketed for healing and recovery. The human evidence is close to nonexistent.
Evidence: Animal studies, almost no human data
TB-500
Synthetic peptide fragment
Sold alongside BPC-157 for the same claimed purposes, with the same evidence problem.
Evidence: Animal studies, no human trials
CJC-1295
GHRH analogue
Sold to raise your own growth hormone. Almost always paired with ipamorelin, and prohibited in all sport.
Evidence: No human trials supporting marketed claims
Ipamorelin
Growth hormone secretagogue
A discontinued drug candidate, now sold as a research chemical alongside CJC-1295.
Evidence: Abandoned in development, no supporting human trials
AOD-9604
Growth hormone fragment
A fat-loss peptide that was tested properly in humans and failed.
Evidence: Human trials did not support the claims
MK-677
Growth hormone secretagogue, non-peptide
Orally active, frequently mis-sold as a SARM or a supplement, and not a peptide at all.
Evidence: Human trials exist, no approval
Melanotan II
Synthetic melanocortin receptor agonist
Sold as a tanning product. The MHRA has warned about it repeatedly.
Evidence: Limited early human studies